1Axel Eigelshover and Kathrin Stember, "Germany New Transfer Pricing Rules", 15 International Transfer Pricing Journal (2008) .
2Fris, Pim, Gonnet, Sebastien, "A European View on Transfer Pricing after Glaxo, Tax Planning International Transfer Pricing", in International Information for International Business, The Bureau of National Affairs, Washington D. C, 2006.
3Giammarco Cottani, "Transfer Pricing and Intangibles: Summary of Discussion at the 61 st IFA Congress in Kyoto", 15 IBFD International Transfer Pricing Journal (2008) .
4Hamaekers, Hubert, "The Ann's Length--How Long?"2 International Transfer Pricing Journal (2007).
5International Fiscal Association, 2007, Cahiers de Droit Fiscal International by the International Fiscal Association, 61st Congress of the International Fiscal Association, Kyoto, 2007, Volume 92a, Subject 1 Transfer Pricing of Intangibles.
6Liantang He, Xiaoyue Wang &Ymin Sun, "China SAT Analysis of U.S. GlaxoSmithKline Case", 16 Tax Management Transfer Pricing Report (2007) .
7Musseli, Andrea, Marchetti Hunter, Donatella, "Glaxo Transfer Pricing Case: Economic Rationale, Legal Framework and International Issues", 3 International Transfer Pricing Journal (2007) .
8Sharnon Burnett and Dariene Pulliam, "Glaxo Smith-Kline and the IRS Finally Find Relief with Zantac", 78 The CPA Journal (2008) .
9International Fiscal Association, Cahiers de Droit Fiscal International by the International Fiscal Association, 61^st Congress of the International Fiscal Association, Kyoto, 2007, Volume 92a, Subject 1 "Transfer Pricing of Intangibles" .
10Fris, Pim, Gonnet, Sebastien, "A European View on Transfer Pricing after Glaxo, Tax Harming International Transfer Pricing", International Information for International Business, The Bureau of National Affairs, Washington D. C, 2006.
